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Abstract There has been little investigation on the
association between cognitive impairment and the micro-
bleeds (MBs) frequently seen in subcortical vascular
dementia (SVaD). One possible mechanism of cognitive
decline in individuals with SVaD could be disruption of
cholinergic fibers by vascular lesions. Central cholinergic
circuits in human brain can be tested non-invasively by
means of a transcranial magnetic stimulation (TMS) pro-
tocol named short latency afferent inhibition (SAI) of
motor cortex. In the present study, we used this test in
SvaD patients with and without MBs. SAI was evaluated in
13 SVaD patients with MBs (MB-positive group) and the
data were compared with those from a group of 15 SVaD
patients without MBs (MB-negative group) and with those
from 20 healthy subjects. Moreover, we studied covariation
of individual SAI values with the Mini-Mental State
Examination (MMSE) total score and subscores. SAI was
significantly reduced in the MB-positive group when
compared with the MB-negative group and the control
subjects. Total MMSE score, ‘‘attention and calculation’’
and ‘‘orientation’’ subscores were significantly lower in the
MB-positive group than in the MB-negative group; SAI
showed a positive correlation with total MMSE score.
Adjustment for age, gender, education, presence of lacu-
nae, severe white matter hyperintensities or severe peri-
ventricular hyperintensities did not affect these findings.
This study provides novel physiological evidence that MBs
have an impact on central cholinergic function that is
independent of the extent of associated white matter
changes and ischaemic stroke. This finding shows that
TMS have potential diagnostic and therapeutic implica-
tions. TMS studies may help in evaluating the causes of
cognitive impairment in cerebrovascular diseases.
Keywords Microbleeds ! Subcortical vascular dementia !
Transcranial magnetic stimulation ! Short latency afferent
inhibition ! Mini-Mental State Examination
Introduction
Small-vessel disease (SVD), particularly of an ischemic
nature, is generally accepted as a major risk factor for sub-
cortical vascular dementia (SVaD). With recent advent of
T2* gradient-echo magnetic resonance imaging (GE-MRI)
many studies demonstrated that SVD can produce not only
ischemia, but also microbleeds (MBs) (Koennecke 2006;
Viswanathan and Chabriat 2006). Since MBs are a mani-
festation of pathology affecting cerebral small vessels, they
are particularly associated with lacunar stroke, cerebral white
matter lesions and hypertension (Kwa et al. 1998; Kato et al.
2002). MBs are characterized histologically by the presence
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of hemosiderin around small vessels (Fazekas et al. 1999;
Tanaka et al. 1999), and appear as small, dot-like lesions of
low signal intensity within the brains of patients with
haemorrhagic and ischaemic stroke, patients with hyperten-
sion, and a smaller proportion of healthy elderly subjects
(Chan et al. 1996; Offenbacher et al. 1996; Kwa et al. 1998;
Roob et al. 2000). Increasing attention has been paid to
associations between cognitive dysfunction and brain MBs.
Central cholinergic mechanisms are believed to modulate
cognitive and attentional processes in humans (Kasa et al.
1997; Bartus 2000); impaired central cholinergic neuro-
transmission has a central role in patients with Alzheimer’s
disease (AD), whereas cholinergic deficit seems to be less
relevant in the pathogenesis of SvaD. Interestingly, in AD
brain MBs are of special interest as they may play a crucial
role in the pathophysiology of the disease (Cordonnier and
van der Flier 2011). However, the potential link between
MBs and cholinergic function has not been clearly
established.
Central cholinergic circuits of human brain can be tested
non-invasively by coupling peripheral nerve stimulation
with transcranial magnetic stimulation (TMS) of motor
cortex. Muscle responses recorded in hand muscles after
TMS of the contralateral motor cortex can be suppressed
by electrical stimulation of the median nerve if the time
interval between stimulation of median nerve and motor
cortex is 2–8 ms longer than the time taken by the
peripheral nerve afferent input to reach the cortex
(Tokimura et al. 2000). This effect, named short latency
afferent inhibition (SAI), is produced by inhibitory inter-
actions within the cerebral cortex (Tokimura et al. 2000; Di
Lazzaro et al. 2004a). SAI has been shown in healthy
subjects to be sensitive to the blockage of muscarinic
acetylcholine receptors (Di Lazzaro et al. 2000) and is
impaired in cholinergic forms of dementia, such as AD and
dementia with Lewy bodies (Di Lazzaro et al. 2002, 2004b,
2007) while it is normal in non-cholinergic forms of
dementia such as fronto-temporal dementia (Di Lazzaro
et al. 2006). In previous TMS studies, a reduced SAI was
found in patients with vascular dementia but not to the
same extent as AD. Nardone et al. (2008) reported that SAI
responses in patients with SVaD varied widely, ranging
from normal to markedly reduced values. In another TMS
study significant SAI abnormalities were disclosed in 3 out
of 12 patients with vascular dementia (Di Lazzaro et al.
2008).
The objective of the present study was to investigate
central cholinergic circuits in SVaD patients with and
without MBs. We evaluated SAI in a group of patients with
SvaD and MBs and compared the data with those from a
group of SVaD patients without MBs and a control group
of age-matched healthy individuals. Furthermore, we ana-
lyzed correlation between this putative marker of central
cholinergic activity, presence of MBs and global cognitive
function.
Materials and methods
Patients
We examined 28 patients (17 men and 11 women, mean
age 69.5 years, range 57–79 years, 26 right-handed) who
met the clinical and imaging criteria of SvaD proposed by
Erkinjuntti et al. (2000) and had undergone GE-MRI. MBs
were detected in the brain for 13 patients (eight men and
five women, mean age 69.7 years, range 58–78 years, 12
right-handed).
Twenty age-matched neurologically healthy controls
(13 men and 7 women, mean age 69.2 years, range
55–79 years, 19 right-handed) constituted the control
group. None of the controls have MBs.
Exclusion criteria were: inability to undergo cerebral
MRI; other concomitant or pre-existing major neurological
disease, including epilepsy, presence of major cortical
infarcts, evidence of concomitant dementia such as AD,
frontotemporal, or reversible dementias; evidence of
depression, other psychiatric diseases, drug addiction;
systemic diseases or traumatic brain injuries.
All the selected patients were able to understand and
carry out the simple tasks required for this electrophysio-
logical study, such as to contract a hand muscle or to keep
fully relaxed.
None of the patients were treated with anticholinergic
drugs before the study. Administration of all drugs that affect
motor cortex excitability in patients and control subjects was
discontinued at least 2 weeks before the study.
Patients provided informed consent before participation
in this study, which was performed according the Decla-
ration of Helsinki and approved by the institutional Ethics
Committee.
Magnetic resonance imaging
MRI was performed using a 1.5-T scanner. MBs were
defined on GE-MRI as homogeneous rounded areas of
signal loss, with a diameter of 2–10 mm. Two investigators
(P.G., S.G.) who were blinded to subject data reviewed the
number and location of MBs. Symmetrical hypointensities
in the globus pallidum likely to represent calcification and
flow void artifacts of pial vessels, as well as hypointense
lesions within the subarachnoid space, were disregarded.
Moreover, to differentiate MBs from other intra-axial
lesions with a hemorrhagic component, only areas of signal
loss that were not locally associated with other abnormal-
ities were counted as MBs.
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Nine patients displayed only supratentorial MBs and
four patients showed both supratentorial and infratentorial
MBs. The total number of MBs in the 13 patients was
4,147 and the number of MBs per patient ranged from 4 to
248 with a median number of 17. MBs were most com-
monly distributed in the cortex and basal ganglia; the
cortical MBs were most pronounced in the frontal area.
White matter hyperintensities (WMH), periventricular hy-
perintensities (PVH), and lacunae were independently
reviewed by 2 of the authors (F.C., S.G.) who were blinded
to subject data. Severity of WHM or PVH on both T2-
weighted and fluid-attenuated inversion recovery-weighted
images was rated according to the Fazekas scale (WMH:
grade 1, punctate; grade 2 early confluence and grade 3
confluent; and PVH: grade 1, caps or lining; grade 2,
bands; and grade 3, irregular extension into the deep white
matter) (Fazekas et al. 1987).
The lacunar infarction was defined as a focal, small and
sharply demarcated lesion, with a diameter of 3–15 mm
showing low signal on T1-, high signal on T2-weighted
images, and perilesional halo on fluid-attenuated inversion
recovery images.
The main demographic characteristics and MRI features
of the patients are reported in Table 1.
Neuropsychological examination
Global cognitive function was assessed using the Mini-
Mental State Examination (MMSE) (Folstein et al. 1975).
MMSE is used worldwide as method to assess cognitive
function; this test was chosen in this preliminary study also
because it has been used in a recent study that explored the
correlation between MBs and cognitive function (Yakushiji
et al. 2008).
Transcranial magnetic stimulation
TMS was performed using a High-power Magstim 200
magnetic stimulator (Magstim Co., Whitland, Dyfed, UK)
connected to a Bistim module throughout all measure-
ments. A figure-of-eight coil with external loop diameters
of 9 cm was held over the motor cortex at the optimum
scalp position to elicit motor responses in the first dorsal
interosseous (FDI) muscle. The dominant hemisphere was
selected for stimulating patients and healthy subjects. The
induced current flows in a postero-anterior direction. Motor
evoked potentials (MEPs) were recorded via two 9 mm
diameter Ag–AgCl electrodes with the active electrode
applied over the motor point of the muscle and the refer-
ence on the metacarpophalangeal joint of the index finger.
MEPs were amplified and filtered (bandwidth 3–3,000 Hz)
by D150 amplifiers (Digitimer, Welwyn Garden City,
Hertfordshire, UK).
We evaluated the following TMS parameters: the resting
motor threshold (RMT), the central motor conduction time
(CMCT), the short latency intracortical inhibition (SICI)
and intracortical facilitation (ICF) to paired TMS, and the
short latency afferent inhibition (SAI).
RMT was defined as the minimum stimulus intensity
that produced a liminal motor evoked response (about
50 lV in 50% of 10 trials) at rest. CMCT was calculated by
subtracting the peripheral conduction time from spinal cord
to muscles from the latency of responses evoked by cortical
stimulation with the formula: MEP latency - (F latency ?
M latency - 1)/2 (Rossini et al. 1994). SICI and ICF were
studied using the technique of Kujirai et al. (1993). Two
magnetic stimuli were given through the same stimulating
coil over the motor cortex and the effect of the first (con-
ditioning) stimulus on the second (test) stimulus was
investigated. The intensity of the conditioning stimulus was
set to 80% RMT; the second, test, shock intensity was
adjusted to evoke a MEP in relaxed FDI with an amplitude
of approximately 1 mV, peak-to-peak.
The timing of the conditioning shock was altered in
relation to the test shock. Inhibitory interstimulus intervals
(ISIs) of 2, 3 and 5 ms and facilitatory ISIs of 7, 10 and
20 ms were investigated. Ten stimuli were delivered at
each ISI. For these recordings, muscle relaxation is very
important and the subject was given audiovisual feedback
at high gain to assist in maintaining complete relaxation.
The presentation of conditioned and unconditioned trials
was randomized. The amplitude of the conditioned EMG
responses was expressed as the percentage of the amplitude
of the test EMG responses. The amplitudes of the condi-
tioned responses were averaged obtaining grand mean
amplitudes of the three inhibitory and of the three facili-
tatory ISIs.
SAI was studied using the recently described technique
(Tokimura et al. 2000). Conditioning stimuli were single
pulses (200 ls) of electrical stimulation (with the cathode
positioned proximally) applied through bipolar electrodes
to the median nerve at the wrist. The intensity of the
conditioning stimuli was set at just over motor threshold
for evoking a visible twitch of the thenar muscles. The
intensity of the test cortical magnetic shock was adjusted to
evoke a muscle response in relaxed FDI with an amplitude
of approximately 1 mV peak-to-peak. The conditioning
stimulus to the peripheral nerve preceded the test magnetic
cortical stimulus. ISIs were determined relative to the
latency of the N20 component of the somatosensory
evoked potential evoked by stimulation of the median
nerve. In the right-handed subjects, the active electrode for
recording the N20 potential was attached 3 cm posterior to
C3 (10-20 system), and the reference was 3 cm posterior to
C4 (vice versa in the left-handed subjects. Five hundred
responses were averaged to identify the latency of N20
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peak. ISIs from the latency of the N20 component plus
2 ms to the latency of the N20 component plus 8 ms were
investigated in steps of 1 ms.
Eight stimuli were delivered at each ISI. We calculated
an average of the MEP obtained after cortical magnetic
stimulation alone and of the MEP obtained by conditioning
cortical magnetic stimulus with a peripheral stimulus to the
median nerve at the wrist at the seven different ISIs stud-
ied. The amplitude of the conditioned MEP was expressed
as percentage of the amplitude of the test MEP. The per-
centage inhibition of the conditioned responses at the seven
different ISIs was averaged to obtain a grand mean. Sub-
jects were given audio-visual feedback at high gain to
assist in maintaining complete relaxation.
To clarify a possible spinal or peripheral contribution on
the motor cortex excitability parameters, supramaximal
stimulation (0.2-ms square-wave constant current pulses)
of the ulnar nerve at the wrist was used to assess spinal and
peripheral motor excitability. While FDI was relaxed, the
peak-to-peak amplitude of F waves (average, 20 trials) and
CMAP (maximum, 3 trials) were determined. We identi-
fied the F waves according to the criteria reported by the
International Federation of Clinical Neurophysiology as
responses that are variable in their latency, amplitude and
configuration but that which occur grouped with a consis-
tent range of latency (Kimura et al. 1994).
To test if SAI was effectively sensitive to changes in
cholinergic activity, RMT and SAI were examined in four
Table 1 Demographic and MRI parameters of patients with SVaD
Patients Demographic variables Neuroradiological measurements
Age (years) Gender Education
(years)
Presence
of lacune
Presence
of WMH
Presence
of PVH
MB-negative group
1 75 M 8 ? 2 1
2 68 M 6 – 2 2
3 57 F 8 – 2 1
4 79 M 5 – 1 0
5 66 F 10 – 2 2
6 60 M 8 ? 2 2
7 72 M 8 – 3 1
8 75 M 10 – 1 1
9 64 F 13 ? 3 2
10 76 M 5 ? 1 1
11 74 F 8 – 2 0
12 72 F 17 ? 2 2
13 64 M 8 – 1 0
14 71 M 17 ? 1 0
15 66 F 10 – 2 1
MB-positive group
1 65 F 8 ? 1 0
2 75 M 5 – 2 1
3 74 M 8 – 2 2
4 68 M 5 ? 3 1
5 78 F 13 ? 2 1
6 66 F 8 ? 3 2
7 70 M 17 – 1 0
8 58 M 10 – 1 1
9 74 F 9 – 1 0
10 72 M 8 ? 2 1
11 71 M 7 ? 2 2
12 62 F 15 – 1 2
13 73 M 8 ? 2 1
WMH white matter hyperintensities. Grade 1: punctuate; grade 2: early confluence; grade 3: confluent. PVH periventricular hyperintensities.
Grade 1: caps or lining; grade 2: bands; grade 3: irregular extension into the deep white matter
1352 R. Nardone et al.
123
patients of the MB-positive group and in four patients of the
MB-negative group before and after the administration of a
single dose of 5 mg of the acetylcholinesterase (AchE)
inhibitor donezepil. Measurements were made before and
4 h after the administration, when AchE inhibition in the
cerebrospinal fluid is maximal (Rogers and Friedhoff 1998).
Statistical analysis
The electrophysiological parameters of the MB-positive
group, the MB-negative group and the control group were
compared by means of analysis of variance (ANOVA)
F tests and t tests. Similar analyses were performed to
explore the correlation between MMSE scores and the
presence of MBs. Where of interest, Bonferroni corrected
post hoc comparisons were conducted.
The effects of donezepil on RMT and SAI were assessed
by means of a paired t test. p value\0.05 was taken as the
significant threshold for all tests.
For the SvaD patients, the relation between SAI and
neuropsychological tests (MMSE total score and sub-
scores) was studied using the Pearson correlation coeffi-
cient and the Spearman rank correlation coefficient. Then,
multiple linear regression was used to determine the cor-
relation between SAI, presence of MBs and neuropsycho-
logical tests (MMSE total score and subscores), corrected
for partial confounding by demographic variables and the
remaining MRI findings (WMHs, PHVs, lacunar infarcts).
We considered the linear model with SAI as dependent
variable (yi), MB-positive group indicator (MBi) and
MMSE score (Si) as explanatory variables with interaction:
yi ¼ b0 þ b1MBi þ b2Si þ b3MBiSi þ ei ð1Þ
where ei are i.i.d. Gaussian error term. Significant inter-
action coefficient b3 implies different regressions of SAI on
MMSE for the two MB groups. Correction for partial
confounding by demographic variables and MRI mea-
surements reported in Table 1 was accomplished by their
introduction as extra-explanatory variables in model (1)
one at the time.
Results
SAI values of the SVaD patients and the control subjects are
shown in the Table 2. ANOVA F test showed a significant
difference between the mean amount (denoted by l) of SAI
among the three groups (F(2,45) = 46.729, p\ 0.0001).
Since the MB-negative group displayed a larger variability
than the other two groups, we used t test with Welch
approximation for post hoc comparison. SAI was signifi-
cantly reduced in the MB-positive group (lpos = 83.0%)
than in the MB-negative group (lneg = 68.8%) and in the
normal controls (lcontr = 45.85%). Multiple t tests showed
that lpos[ lneg[ lcontr, (p = 0.008 after Bonferroni
correction).
RMT, CMCT, SICI, ICF, CMAP and F wave did not
differ significantly between the two patient groups and the
control group (ANOVA not significant for all F tests). All
neurophysiological data are summarized in the Table 3.
RMT was not significantly modified by the administra-
tion of a single oral dose of donezepil (p = 0.17, paired
t test). In contrast, SAI was significantly increased after
donezepil administration (the mean amplitude of the con-
ditioned response was 85.62% of the control size before the
administration and 64.50% after the administration of
donezepil; p\ 0.001, paired t test).
Differences in MMSE (total score and subscores)
between MB-negative group, MB-positive group and con-
trol group were all significant (Table 4); t tests showed
significant differences for MMSE total score, ‘‘orientation’’
and ‘‘attention and calculation’’ subscores between the two
MB groups (p = 0.004, 0.01 and 0.0014, respectively).
In the SVaD patients, SAI was positively correlated with
MMSE total score and the 5 subscores: reduced SAI values
were associated with lower scores in the neuropsycholog-
ical tests (Table 5). Estimation of model (1) with Si as
MMSE total score showed that the regression coefficients
are all statistically significant with b3[ 0 (p = 0.003). The
Table 2 SAI (% of test response) of the SVaD patients and control
subjects
MB-negative group MB-positive group Control group
Patient SAI Patient SAI Subject SAI
1 51 1 72 1 48
2 70 2 85 2 55
3 74 3 88 3 35
4 49 4 94 4 51
5 88 5 74 5 53
6 46 6 67 6 35
7 84 7 86 7 57
8 82 8 92 8 39
9 59 9 85 9 45
10 55 10 84 10 52
11 82 11 82 11 44
12 79 12 88 12 31
13 84 13 82 13 54
14 49 14 47
15 80 15 43
16 40
17 62
18 36
19 55
20 35
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hypothesis of normality of the residuals is respected as
shown by the Kolmogorov–Smirnov test (H0: ei * N(0,1),
p = 0.56). We plot the data in two panels that show sep-
arate fitted regression lines in Fig. 1. Notably, the corre-
lation between SAI and MMSE was negative in both
patient groups (as shown by the slopes b2\ 0 and
b2 ? b3\ 0) and the regression line of MMSE to SAI was
steeper for the MB-negative group.
Finally, adjustment for age, gender, education, presence
of lacunae, severe PVH and severe WMH did not affect the
estimation results of model (1): when added as explanatory
variables, estimation showed no significant effect, and the
Table 3 Explanatory comparison of the neurophysiological data of the SvaD patients (MB-positive and MB-negative patient groups) and the
control subjects
MB-positive group MB-negative group Control group F(2,45)
Mean (SD) Mean (SD) Mean (SD) p value
SAI (% of test response) 83.00 (7.80) 68.80 (15.46) 45.85 (8.90) <0.001
RMT (% of MSO) 48.92 (8.74) 48.27 (7.80) 47.90 (8.51) 0.9427
CMCT (ms) 6.18 (0.48) 6.20 (0.56) 6.09 (0.61) 0.8238
SICI (% of test response)a 34.92 (9.80) 35.80 (11.49) 34.35 (10.37) 0.8853
ICF (% of test response)b 117.31 (26.44) 118.27 (27.20) 116.65 (26.22) 0.9601
CMAP (mV) 7.67 (0.73) 7.61 (0.96) 7.63 (0.95) 0.9826
F wave (lV) 254.92 (50.89) 240.80 (54.40) 242.35 (45.80) 0.7159
Bold type indicates significant differences among the three groups
SAI short latency afferent inhibition, RMT resting motor threshold, MSO maximum stimulator output, CMCT central motor conduction time,
SICI short latency intracortical inhibition, ICF intracortical facilitation, CMAP compound muscle action potential
a Grand mean of the SICI at the three ISIs studied
b Grand mean of the ICF at the three ISIs studied
Table 4 Mini-Mental State Examination (MMSE) total score and subscores in the MB-positive and MB-negative groups
MB-negative group MB-positive group Control group F(2,45)
Mean (SD) Mean (SD) Mean (SD) p value
MMSE total 22.07 (1.67) 19.92 (1.93) 29.65 (0.59) <0.001
MMSE orientation 8.33 (0.72) 7.62 (0.65) 10.00 (0.00) <0.001
MMSE immediate 2.60 (0.51) 2.38 (0.65) 3.00 (0.00) <0.001
MMSE atten. and calc. 1.60 (0.63) 0.77 (0.60) 4.85 (0.37) <0.001
MMSE delayed rec. 1.87 (0.35) 1.62 (0.51) 2.85 (0.37) <0.001
MMSE language 7.67 (0.82) 7.54 (0.66) 8.95 (0.22) <0.001
Bold type indicates significant differences between the two patient groups
Table 5 Correlation between SAI and MMSE total score and subscores in the patients with SVaD evaluated by means of Pearson and Spearman
correlation coefficients
MMSE total MMSE
orientation
MMSE
immediate rec.
MMSE
atten. and calc.
MMSE
delayed rec.
MMSE
language
Pearson
Estimate 20.861 20.794 20.417 20.523 20.314 20.552
p value <0.0001 <0.0001 0.027 0.004 0.104 0.002
Spearman
Estimate -0.896 20.774 20.397 20.553 20.353 20.620
p value <0.0001 <0.0001 0.036 0.002 0.065 <0.001
Bold type indicates significant correlation
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significant relationship between MMSE, MB grouping and
SAI was not influenced by their introduction.
Discussion
We first explored the relationship between MBs, SAI and
cognitive function in patients with SvaD. Our study shows
that SAI, a putative marker of cholinergic cortical activity,
is significantly more abnormal in the patients with SVaD
and MBs than in SVaD patients without MBs who also
present a significantly reduced SAI as compared with
normal controls.
The recently reported interaction of SAI with the other
inhibitory process N100 EEG response has provided fur-
ther evidence of the cortical origin of SAI (Bikmullina
et al. 2009). Moreover, we failed to find in the present
study significant differences in F wave between groups that
might be expected if spinal mechanisms are contributory.
SAI is thought to be related to central cholinergic activity
because in normal subjects it can be reduced or abolished by
intravenous injection of the muscarinic antagonist scopol-
amine (Di Lazzaro et al. 2000) and is modulated by Ach in
healthy subjects (Di Lazzaro et al. 2005a, 2006; Fujiki et al.
2006). SAI is also influenced by GABAergic drugs such as
some benzodiazepines in healthy subjects (Di Lazzaro et al.
2005a, b, c) and by dopaminergic drugs in patients with
Parkinson disease (Sailer et al. 2003). Preliminary data
suggest that other neurotransmitters/neuromodulators are
likely not involved in the regulation of SAI in that quetia-
pine, an antagonist at multiple neurotransmitter receptors in
the brain such as serotonin 5HT1A and 5HT2, dopamine D1
and D2, histamine, and adrenergic a1 and a2 receptors, does
not modify SAI in healthy subjects (Di Lazzaro et al. 2005b).
Therefore, SAI is thought to represent a non-invasive way of
testing the integrity of some cholinergic cortical circuits
(Ziemann 2004), while the contribution of neurotransmitters
other than Ach is not well understood. On the other hand, it
has been recently reported that dopamine modifies SAI in
AD (Martorana et al. 2009). Therefore, it should be con-
sidered that other neurotransmitters such as dopamine may
be able to modulate cortical cholinergic function in AD
patients.
Interestingly, administration of a single dose of the
AchE inhibitor donezepil improved SAI in our patients,
similarly to that previously reported in AD patients. These
results suggest that the evaluation of the effects of the
AchE inhibitors on SAI could be useful in the management
of SvaD patients (similar to that reported in patients with
AD) because it is currently impossible to predict an indi-
vidual therapeutic response in these patients.
We cannot rule out the possibility that in some patients
the cholinergic dysfunction was due to a concurrent AD
pathology. The patients with abnormal SAI could have
concomitant neuropathological changes of AD and thus
represent the percentage of patients with a mixed form of
dementia. Indeed, neuropathological studies of VD have
demonstrated that 25–30% of patients with the clinical
diagnosis of VD show the concomitant neuropathology of
AD (Kalaria and Ballard 1999; Vinters et al. 2000).
However, SvaD and AD can be distinguished by the mode
of onset and progression of the cortical deficits. Memory
impairment, usually the first and more severe cognitive
manifestation of AD, was quite mild in our patients while
they display significant poor performance on ‘‘attention
and calculation’’ tasks, similar to that previously reported
(Yakushiji et al. 2008).
A possible explanation for the SAI abnormality is
that the subcortical lesions in SVaD interrupt ascend-
ing cholinergic axons determining cortical cholinergic
MMSE tot score
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Fig. 1 Data on patients with
SVaD showing the correlation
between MMSE total score and
SAI by estimation of the
multiple linear regression model
(1). Left panel MB-negative
group, right panel MB-positive
group
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denervation. White matter lesions may directly affect
cholinergic projection (Selden et al. 1998; Swartz et al.
2003), and preclinical (Togashi et al. 1994; Kimura et al.
2000) as well clinical evidence (Gottfries et al. 1994;
Martin-Ruiz et al. 2000) suggest that the cholinergic sys-
tem might also be involved in SVaD. Mesulam et al. (2003)
demonstrated in a patient with cerebral autosomal domi-
nant arteriopathy with subcortical infarcts and leukoen-
cephalopathy (CADASIL) that pure white matter infarcts,
similar to those seen in SVaD, can cause cortical cholin-
ergic denervation, but in patterns that vary from those seen
in AD. Interestingly, in CADASIL patients the amount of
SAI was found to be significantly smaller than in normal
subjects (Manganelli et al. 2008).
Clinical implications of MBs have rarely been studied.
Despite considerable interest in MBs as a marker of
bleeding-prone small-vessel angiopathy, they have initially
been considered to be clinically silent (Kwa et al. 1998;
Kato et al. 2002; Tsushima et al. 2003). However, since
they are located in widespread cortical and basal ganglia
regions and are histologically characterized by tissue
damage, they could cause cognitive dysfunction. More-
over, histopathological data that MBs show not only hae-
mosiderin deposition but also surrounding gliosis, and
sometimes frank necrosis or infarction also support the
clinical importance of MBs (Tanaka et al. 1999).
Werring et al. (2004) found that stroke patients with
MBs were more impaired at frontal executive functions
than those without MBs, and postulated that MBs located
in the frontal lobe and the basal ganglia might have caused
it. There were two studies that investigated MBs in patients
with vascular dementia (Hanyu et al. 2003; Cordonnier
et al. 2006). One study enrolled 31 patients with vascular
dementia (not necessarily SvaD) and reported the fre-
quency of MBs of 65% (Cordonnier et al. 2006); the other
study that involved Asian SvaD patients reported the fre-
quency of 77% (Hanyu et al. 2003). Moreover, a recent
review article suggested that the cognitive impairment of
patients with cerebral amyloid angiopathy (CAA) might
be associated with the number of baseline hemorrhages
(Viswanathan and Chabriat 2006). The number of micro-
hemorrhages in the frontal lobes and basal ganglia was the
only independent predictor of executive dysfunction in the
CAA patients; however, the investigators did not evaluate
all potential confounders, particularly the number or loca-
tion of associated lacunar infarctions. In agreement with
our findings, another study showed that MBs affect the
general cognitive dysfunction and the severity of dementia
in patients with SvaD (Won Seo et al. 2007). Yakushiji
et al. (2008) recently also reported that MBs appear to be
primarily associated with global cognitive dysfunction.
The results of the present study are thus consistent with
the more recent literature on the clinical significance of the
MBs in SVaD and further support the notion that not only
ischemia but also MBs are primary pathomechanisms of
cognitive impairment. Only in CADASIL patients MBs
were previously found not to be associated with cognitive
dysfunction (Liem et al. 2007). This finding could be
explained by the more extensive ischemic lacunar changes
occurring at a younger age in CADASIL.
The mechanisms underlying the pathological association
between MBs and cognitive dysfunction remain still
unclear. A histopathologic study on MBs in patients with
primary cerebral hemorrhage has shown that the presence
of MBs indicated widespread damage of arterioles by
hypertension or amyloid deposition (Fazekas et al. 1999).
The location of brain MBs may be of importance, with
cortico-subcortical brain MBs being more strongly related
to CAA than brain MBs in deep of infratentorial locations
(Cordonnier and van der Flier 2011); however, this issue
has not been addressed in this preliminary study. Anyway,
the presence of MBs may thus imply much more severe
disruption of the neural network between cortical and
subcortical structures than ischemic SVDs. MBs would be
expected to cause cognitive impairment if they disrupt
strategically important white matter tracts or eloquent
cortical areas.
Since MBs are particularly common in the white matter
regions (Offenbacher et al. 1996), it could be hypothesized
that executive functions would be most affected, due to
disruption of frontal–basal ganglia connections.
Interestingly, patients with Parkinson’s disease and
dementia have also been shown to display significantly
poor performance on ‘‘attention and calculation’’ tasks in
the MMSE (Yakushiji et al. 2008). This cognitive deficit is
considered to result from severe dysfunction of cholinergic
pathways in the frontal-subcortical circuits (Bohnen et al.
2003, 2006). In common with previous studies, we
observed MBs most frequently in the basal ganglia as well
as in the frontal regions. Predominant occurrence of MBs
in these regions may thus cause executive dysfunction
(Werring et al. 2004). This hypothesis requires confirma-
tion by future studies employing more detailed neuropsy-
chological tests which offer higher sensitivity for the
assessment of cognitive functions (in particular the exec-
utive functions) in patients with SvaD (O’Sullivan et al.
2005). The association we have found between MMSE
scores and the presence of MBs as well as with SAI values
would be more even prominent if it would have used more
sophisticated neuropsychological testing.
Our data indicate that the cumulative effect of MBs on
cognition appears to be independent of coexisting ischae-
mic cerebrovascular disease, and in particular is indepen-
dent of the severity of ischaemic SVaD as assessed by MRI
white matter changes. The finding that MBs are associated
with cholinergic dysfunction has potential diagnostic and
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therapeutic implications. It would be of particular interest
to explore in future studies the responsiveness of patients
with MBs, stratified according to their cholinergic dys-
function, defined using SAI, to AchE inhibitors.
TMS studies may be important for evaluating the causes
of cognitive impairment in cerebrovascular disease. Thus,
in patients with cerebrovascular risk factors and cognitive
impairment, T2*-weighted GE-MRI may be a helpful
adjunct to standard MRI in clarifying the mechanism of
cognitive impairment.
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